Kai Nishimura
Tokyo Institute of Technology
13 Papers
Kai Nishimura is an academic researcher from Tokyo Institute of Technology. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Cyclic RGD-Functionalized closo-Dodecaborate Albumin Conjugates as Integrin Targeting Boron Carriers for Neutron Capture Therapy
Kazuki Kawai,Kai Nishimura,Satoshi Okada,Shinichi Sato,Minoru Suzuki,Takushi Takata,Hiroyuki Nakamura +6 more
TL;DR: In vivo BNCT study revealed that the cRGD peptide ligand combination enhanced accumulation of MID-BSA into tumor cells in U87MG xenograft models.
36
Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model
Hideki Kashiwagi,Shinji Kawabata,Kohei Yoshimura,Yusuke Fukuo,Takuya Kanemitsu,Koji Takeuchi,Ryo Hiramatsu,Kai Nishimura,Kazuki Kawai,Takushi Takata,Hiroki Tanaka,Tsubasa Watanabe,Minoru Suzuki,Shin-Ichi Miyatake,Hiroyuki Nakamura,Masahiko Wanibuchi +15 more
TL;DR: In conjugate (MID-AC) as discussed by the authors was developed as a boron carrying system for particle irradiation therapy (BNCT), which is a biologically targeted, cell-selective particle ionization therapy that utilizes the nuclear capture reaction of bors and neutrons.
16
Improved Boron Neutron Capture Therapy Using Integrin αvβ3-Targeted Long-Retention-Type Boron Carrier in a F98 Rat Glioma Model
Kohei Tsujino,Hideki Kashiwagi,Kai Nishimura,Ryozo Kayama,Kohei Yoshimura,Yusuke Fukuo,Hiroyuki Shiba,Ryo Hiramatsu,Naosuke Nonoguchi,Motomasa Furuse,Toshihiro Takami,Shin-Ichi Miyatake,Naonori Hu,Takushi Takata,Hiroki Tanaka,Minoru Suzuki,Shinji Kawabata,Hiroyuki Nakamura,Masahiko Wanibuchi +18 more
TL;DR: In this paper , a novel boron-10 carrier containing maleimide-functionalized closo-dodecaborate (MID), serum albumin as a drug delivery system, and cyclic arginine-glycine-aspartate (cRGD) that can target integrin αvβ3 was developed.
Iodophenyl-conjugated closo-dodecaborate as a promising small boron molecule that binds to serum albumin and accumulates in tumor.
Kai Nishimura,Suzanna Harrison,Kazuki Kawai,Taiki Morita,Kazuki Miura,Satoshi Okada,Hiroyuki Nakamura +6 more
TL;DR: In this article , a boron-conjugated 4-iodophenylbutanamide (BC-IP) was used as an albumin ligand and conjugated with closo-dodecaborate, which was found to be water soluble with low cytotoxicity.
7
Evaluation of the Effectiveness of Boron Neutron Capture Therapy with Iodophenyl-Conjugated closo-Dodecaborate on a Rat Brain Tumor Model
Yoshiki Fujikawa,Yusuke Fukuo,Kai Nishimura,Kohei Tsujino,Hideki Kashiwagi,Ryo Hiramatsu,Naosuke Nonoguchi,Motomasa Furuse,Toshihiro Takami,Naonori Hu,Shin-Ichi Miyatake,Takushi Takata,Hiroki Tanaka,Tsubasa Watanabe,Minoru Suzuki,Shinji Kawabata,Hiroyuki Nakamura,Masahiko Wanibuchi +17 more
TL;DR: This study evaluated the use of boron-conjugated 4-iodophenylbutanamide (BC-IP), a novel borOn compound in BNCT, for the treatment of glioma and suggested that BC-IP, with its unique properties, may be an alternative bor on carrier for BN CT.
2